Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ex vivo-expanded allogeneic NK cell infusion for elderly AML patients in remission who are not eligible for stem cell transplantation
NL-OMON22174Phase 1Active, not recruiting
- Sponsor
- Radboud University Medical Center
- Start
- Oct 2011
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial in acute myeloid leukemia (AML), sponsored by Radboud University Medical Center. Primary endpoint: Safety and dose-limiting toxicity. Started Oct 2011; status: active, not recruiting.
02
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NL-OMON22174.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON22174.